Stockscreener 앱 받기
0.00
100.00%
-9.81
전일 마감가:
$9.81
열려 있는:
$0
하루 거래량:
0
Relative Volume:
0.00
시가총액:
$49.48M
수익:
-
순이익/손실:
$-168.86M
주가수익비율:
0.00
EPS:
-1.68
순현금흐름:
$-125.29M
1주 성능:
-100.00%
1개월 성능:
-100.00%
6개월 성능:
-100.00%
1년 성능:
-100.00%
1일 변동 폭
$0.00
$0.00
1주일 범위
$0.00
$0.00
52주 변동 폭
$0.00
$24.15
알로비르 Stock (ALVR) Company Profile
명칭
Allovir Inc
전화
(617) 433-2605
주소
1100 WINTER STREET, WALTHAM
ALVR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ALVR
Allovir Inc
|
0.00 | 49.48M | 0 | -168.86M | -125.29M | -1.68 |
|
VRTX
Vertex Pharmaceuticals Inc
|
493.84 | 125.74B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
602.64 | 61.57B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
614.76 | 36.40B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.56 | 30.36B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
244.90 | 24.89B | 3.81B | -644.79M | -669.77M | -6.24 |
알로비르 Stock (ALVR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-12-26 | 다운그레이드 | BofA Securities | Buy → Underperform |
| 2023-12-22 | 다운그레이드 | JP Morgan | Overweight → Underweight |
| 2023-12-22 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2023-12-22 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2023-08-18 | 개시 | BofA Securities | Buy |
| 2021-10-19 | 재개 | Morgan Stanley | Overweight |
| 2020-08-24 | 개시 | JP Morgan | Overweight |
| 2020-08-24 | 개시 | Morgan Stanley | Overweight |
| 2020-08-24 | 개시 | SVB Leerink | Outperform |
모두보기
알로비르 주식(ALVR)의 최신 뉴스
Press Release Distribution & PR Platform - ACCESS Newswire
AlloVir, Inc. Sued for Securities Law ViolationsInvestors Should Contact Levi & Korsinsky Before March 19, 2024 to Discuss Your RightsALVR - Louisiana First News
AlloVir Announces FDA Clearance of Investigational New Drug Application for ALVR106, an Allogeneic, Off-The-Shelf, Multi-Virus Specific T Cell Therapy Targeting Four Devastating Respiratory Viruses - marketscreener.com
AlloVir ($ALVR) Is Paying a Settlement to Investors — Here’s How to Get Your Share - TradingView
William Blair Initiates Kalaris Therapeutics With Outperform Rating - MarketScreener
(ALVR) Technical Data - news.stocktradersdaily.com
Kalaris Therapeutics appoints new board chair By Investing.com - Investing.com Canada
The Gross Law Firm Notifies Shareholders of AlloVir, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of March 19, 2024(NASDAQ: ALVR) - MarketScreener
Kalaris Therapeutics appoints new board chair - Investing.com India
Kalaris Expands Board of Directors Appointing Leone Patterson as Chair of Audit Committee - The Manila Times
Kalaris Expands Board Of Directors Appointing Leone Patterson As Chair Of Audit Committee - MarketScreener
Class Action Filed Against AlloVir, Inc. (ALVR) Seeking Recovery for InvestorsContact Levi & Korsinsky - ACCESS Newswire
ALLOVIR INVESTOR DEADLINE APPROACHING: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In AlloVir To Contact Him Directly To Discuss Their Options - MarketScreener
ALVR Bronstein, Gewirtz & Grossman LLC Announces that AlloVir Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - MarketScreener
The Law Offices of Vincent Wong Remind AlloVir Investors of a Lead Plaintiff Deadline of March 19, 2024 - MarketScreener
ROSEN, SKILLED INVESTOR COUNSEL, Encourages AlloVir, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionALVR - MarketScreener
ALLOVIR SHAREHOLDER ACTION REMINDER: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In AlloVir To Contact Him Directly To Discuss Their Options - Marketscreener.com
Levi & Korsinsky Notifies AlloVir, Inc.(ALVR) Investors of a Class Action Lawsuit and Upcoming Deadline - MarketScreener
Kalaris Therapeutics’ chief accounting officer sells shares worth $8,135 - Investing.com India
Kalaris Therapeutics’ chief accounting officer sells shares worth $8,135 By Investing.com - Investing.com UK
Trend Tracker for (ALVR) - Stock Traders Daily
Kalaris and AlloVir Inc. complete merger - Ophthalmology Times
Kalaris Therapeutics Announces Closing of Merger With AlloVir - VisionMonday.com
Parainfluenza Virus Infection Market to Expand Significantly by 2034, States DelveInsight Report | Ansun Biopharma, AlloVir, MedImmune - The Globe and Mail
ROSEN, LEADING TRIAL ATTORNEYS, Encourages AlloVir, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class ActionALVR - Marketscreener.com
ALLOVIR, INC. CLASS ACTION ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a class action lawsuit has been filed in the United States District Court for the District of Massachusetts against AlloVir, Inc. - Marketscreener.com
ALLOVIR, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q) - Marketscreener.com
Kalaris Therapeutics Completes Merger with AlloVir - Marketscreener.com
AlloVir Merges with Kalaris Therapeutics, Inc. - TipRanks
Kalaris Announces Closing of Merger with AlloVir - The Manila Times
Kalaris Therapeutics Completes Merger with AlloVir, Advances Phase 1 Trial of TH103 for Neovascular Retina Diseases - Nasdaq
Kalaris Secures $100M War Chest for Revolutionary Macular Degeneration Treatment - StockTitan
(ALVR) On The My Stocks Page - Stock Traders Daily
Kalaris and AlloVir Announce Stockholder Approval of Merger - VisionMonday.com
AlloVir shareholders approve merger with Kalaris Therapeutics By Investing.com - Investing.com Australia
AlloVir Stockholders Approve Key Amendment and Merger - TipRanks
AlloVir shareholders approve merger with Kalaris Therapeutics - Investing.com
Stockholders Approve Game-Changing Kalaris-AlloVir Merger: What This Means for Retinal Disease Treatment - StockTitan
AlloVir (ALVR) Expected to Announce Earnings on Thursday - The AM Reporter
AlloVir Inc. (ALVR) reports earnings - Quartz
Allovir, Inc. SEC 10-K Report - TradingView
How To Trade (ALVR) - Stock Traders Daily
DEADLINE ALERT: Bernstein Liebhard LLP Reminds AlloVir, Inc. Investors of Upcoming Deadline - ACCESS Newswire
FINAL ALVR DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds AlloVir Inc. Investors to Join the Class Action Lawsuit! - ACCESS Newswire
Lost Money on AlloVir, Inc.(ALVR)? Join Class Action Suit Seeking RecoveryContact Levi & Korsinsky - ACCESS Newswire
Investors who lost money on AlloVir, Inc. (ALVR) should contact Levi & Korsinsky about pending Class ActionALVR - ACCESS Newswire
알로비르 (ALVR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
36.06%
자본화:
|
볼륨(24시간):